All studies
Phase 3RecruitingInterventionalNCT04892173

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma

  • Carcinoma, Squamous Cell
I want to take partRefer a patient8 sites in India (5 recruiting) · 196 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Johnson & Johnson Enterprise Innovation Inc.
Enrolment target
500
Started
10 December 2021
Main results due (estimated)
30 June 2028
Study ends (estimated)
30 June 2028
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
None
Sites
196 · 8 in India
First posted
19 May 2021
Registry updated
3 November 2026

Can you take part?

  • Aged 60 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Age greater than or equal to (\>=) 60 years old
* Biopsy-confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx and a candidate for definitive radiation therapy with or without cetuximab
* Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC
* One primary tumor lesion amendable for intratumoral injection
* Ineligible to receive platinum-based chemotherapy with radiation (at least one of the following):

  1. Estimated creatinine clearance \>= 30 and less than (\<) 50 milliliters/minute (mL/min) (per Cockcroft-Gault equation),
  2. Grade \>= 2 hearing loss or tinnitus,
  3. Grade \>= 2 peripheral neuropathy,
  4. New York Heart Association Class 3
  5. Aged 70-74 years old with Geriatric 8 (G8) score less than or equal to (\<=) 14 or Aged \>= 75 years old
* Eastern cooperative oncology group (ECOG) performance status 0 to 1
* Life expectancy \>= 6 months

Exclusion Criteria:

* Carcinoma of the nasopharynx, paranasal sinus, salivary gland, or thyroid gland; or non-squamous histology or SCC of unknown primary origin
* Clinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition of AJCC
* Loco-regionally recurrent head \& neck cancer that has been previously treated with surgery, radiation therapy, and/or chemotherapy
* Prior or concurrent primary malignancy (including second synchronous head \& neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent
* Ongoing or active infection requiring treatment with antimicrobial therapy within 2 weeks of randomization

What this study is about

In the sponsor’s own words, from the registry.

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

Keywords: LA-HNSCC · NBTXR3 · hafnium oxide · radioenhancer · Radiotherapy · RT · HNSCC · radiation therapy

What participants receive

  • Experimental

    Arm A: JNJ-90301900 (NBTXR3)

    JNJ-90301900 (NBTXR3), as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. JNJ-90301900 (NBTXR3) is given as a dose of 33% of the Gross Tumor Volume.

    Drug: JNJ-90301900 (NBTXR3) · Drug: Cetuximab · Radiation: Radiation Therapy

  • Active comparator

    Arm B: RT alone or RT in combination with cetuximab

    Investigator's choice of RT alone or RT in combination with cetuximab.

    Drug: Cetuximab · Radiation: Radiation Therapy

Interventions

  • JNJ-90301900 (NBTXR3)Drug

    Also known as Functionalized hafnium oxide nanoparticles, NBTXR3

    Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.

  • CetuximabDrug

    Also known as Erbitux

    Solution for infusion

  • Radiation TherapyRadiation

    Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.

What the study measures

Primary outcomes

  1. Progression-free Survival (PFS) Based on Independent Central Review (ICR)

    PFS is defined as time from randomization to local-regional progression (including recurrence), distant progression, or death from any cause, whichever occurs first.

    Time frame: 30 months following first randomized participant

Secondary outcomes

  1. Overall Survival (OS)

    Time from randomization to death from any cause.

    Time frame: 48 months following first randomized participant

  2. Local-regional control

    Time to local regional progression: time from randomization to local-regional progression (including recurrence) or death, whichever occurs first.

    Time frame: 48 months following first randomized participant

  3. Distant control

    Time to distant progression: time from randomization to distant progression or death, whichever occurs first.

    Time frame: 48 months following first randomized participant

  4. Quality of Life over time - QLQ H&N35

    Change from baseline over time in symptoms, function, and health related QOL using the European organisation for research and treatment of cancer (EORTC) questionnaire-head and neck cancer module (QLQ H\&N35).

    Time frame: 48 months following first randomized participant

  5. Quality of Life over time - EQ 5D 5L

    Change from baseline over time in symptoms, function, and health related QOL using the 5 level EuroQol 5 dimension (EQ 5D 5L) instrument.

    Time frame: 48 months following first randomized participant

  6. Safety across duration of study - AEs

    Adverse events (AEs).

    Time frame: 48 months following first randomized participant

  7. Objective Response Rate (ORR)

    Rate of complete response (CR)+partial response (PR) \[RESIST 1.1\].

    Time frame: 48 months following first randomized participant

  8. Duration of Overall Response

    Time from CR or PR to progression of disease, unequivocal clinical progression, or death, whichever occurs first.

    Time frame: 48 months following first randomized participant

  9. Head and Neck Cancer Specific Event-Free Survival

    Time from randomization to loco regional progression (including recurrence), distant progression, or head and neck cancer related death, as per RECIST 1.1, whichever occurs first.

    Time frame: 48 months following first randomized participant

  10. Head and Neck Cancer-Specific Survival

    Time from randomization to head and neck cancer-related death.

    Time frame: 48 months following first randomized participant

Who is running it

Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Johnson & Johnson Enterprise Innovation Inc.
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
NANORAY-312
Other IDs
NANORAY-312, 2024-520386-31-00
  • Johnson & Johnson Enterprise Innovation Inc Clinical trial

    Study director

    Johnson & Johnson Enterprise Innovation Inc.

Study sites(196)

  • M S Ramaiah Memorial Hospital

    Bangalore, India

    Recruiting

  • Tata Memorial Hospital

    Mumbai, India

    Recruiting

  • HealthCare Global HCG Manavata Cancer Centre

    Nashik, India

    Recruiting

  • Rajiv Gandhi Cancer Institute and Research Centre

    New Delhi, India

    Recruiting

  • HCG cancer center

    Vijayawada, India

    Recruiting

  • Apollo Speciality Hospital, Chennai

    Chennai, India

    Completed

  • Meenakshi Mission Hospital and Research Center

    Madurai, India

    Completed

  • Grant Medical foundation Ruby Hall Clinic

    Pune, India

    Completed

  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

    Recruiting

  • City of Hope

    Duarte, California, United States

    Recruiting

  • University of California at San Diego Moores Cancer Center

    La Jolla, California, United States

    Recruiting

  • UCLA Hematology Oncology

    Los Angeles, California, United States

    Recruiting

  • University of California San Francisco

    San Francisco, California, United States

    Recruiting

  • George Washington University Cancer Center

    Washington D.C., District of Columbia, United States

    Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, United States

    Recruiting

  • AdventHealth Orlando

    Orlando, Florida, United States

    Recruiting

  • Moffitt Cancer Center

    Tampa, Florida, United States

    Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia, United States

    Recruiting

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky, United States

    Recruiting

  • Boston Medical Center

    Boston, Massachusetts, United States

    Recruiting

  • Richmond University Medical Center

    Staten Island, New York, United States

    Recruiting

  • Montefiore Medical Center

    The Bronx, New York, United States

    Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, United States

    Recruiting

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina, United States

    Recruiting

  • University of Cincinnati

    Cincinnati, Ohio, United States

    Recruiting

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, United States

    Recruiting

  • Oregon Health And Science University

    Portland, Oregon, United States

    Recruiting

  • University of Pennsylvania Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania, United States

    Recruiting

  • University of Virginia

    Charlottesville, Virginia, United States

    Recruiting

  • Macon Joan Brock Virginia Health Sciences Eastern Virginia Medical Group at Old Dominion University

    Norfolk, Virginia, United States

    Recruiting

  • Medical University Innsbruck

    Innsbruck, Austria

    Recruiting

  • Ordensklinikum Linz GmbH Barmherzige Schwestern

    Linz, Austria

    Recruiting

  • Medizinische Universitaet Wien

    Vienna, Austria

    Recruiting

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

    Recruiting

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

    Recruiting

  • Fundacao Pio XII

    Barretos, Brazil

    Recruiting

  • Nucleo de Ensino e Pesquisa do Instituto Mario Penna

    Belo Horizonte, Brazil

    Recruiting

  • Instituto Do Cancer Do Ceara

    Fortaleza, Brazil

    Recruiting

  • Fundacao Sao Francisco Xavier

    Ipatinga, Brazil

    Recruiting

  • Fundacao Doutor Amaral Carvalho

    Jaú, Brazil

    Recruiting

Showing 40 of 196 sites. 134 recruiting, 62 not recruiting and 0 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

  • Le Tourneau C, Takacsi-Nagy Z, Nuyts S, Thureau S, Liu F, Hoffmann C, Hackman TG, Lesnik M, Debard A, Finzi L, Devisetty K, Vivar OI, Farber LA, Nguyen F, Liem X, Natelauri E, Psyrri A, Burian M, Yu J, Yom SS. Nanoray-312: phase III study of NBTXR3 + radiotherapy +/- cetuximab in elderly, platinum-ineligible locally advanced HNSCC. Future Oncol. 2025 May;21(12):1489-1499. doi: 10.1080/14796694.2025.2496131. Epub 2025 May 5. PMID 40323213
Participant data shared
No

Source: ClinicalTrials.gov record NCT04892173, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.